ImmusanT reports data on novel celiac disease diagnostic approach
ImmusanT, Inc., a clinical-stage company developing Nexvax2®, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.
May 10, 2017 · by · in Nutritional News · Tags: diet, effects, gluten-exposure, hla, nexvax2, nutrition, oncalldietitian.com, the-effects, vaccine-intended
Phase I Trial Of Vaccine Shows Promising Results In Coeliac Disease
The world’s first potential vaccine for coeliac disease has shown promising results for treating coeliac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year. The Phase I trial undertaken in Melbourne, Australia, evaluated the safety, tolerability and bioactivity of the vaccine Nexvax2®, which has been developed for coeliac disease…
May 10, 2011 · by · in Nutritional News · Tags: clinical-trial, coeliac-disease, first-potential, immune system / vaccines, nexvax2, nutritional counseling, the-vaccine, trials-within, vaccine
